Cardiovascular Outcomes and Angiotensin Converting Enzyme Inhibitors: Beyond Blood Pressure Control: Editorial to: “Secondary Prevention of Coronary Disease with ACE Inhibition—Does Blood Pressure Reduction with Perindopril Explain the Benefits in EUROPA?” by Remme et al.

By Verma Anil   Ventura Hector  

Cardiovascular Drugs and Therapy, Vol. 23, Iss. 2, 2009-04 ,pp. : 109-111

Springer Publishing Company

Access to resources Recommend Favorite

L-Type Calcium Channels Modulate the Regression of Left Ventricular Hypertrophy After Ace-Inhibition in Genetic Hypertension

By Vulpis V.   Lograno M.D.   Seccia T.M.   Pirrelli A.  

Pharmacological Research, Vol. 38, Iss. 4, 1998-09 ,pp. : 317-322

Academic Press

Access to resources Recommend Favorite

Atorvastatin: A Pharmacoeconomic Review of its Use in the Primary and Secondary Prevention of Cardiovascular Events

By Plosker Greg L.   Lyseng-Williamson Katherine A.  

PharmacoEconomics, Vol. 25, Iss. 12, 2007-01 ,pp. : 1031-1053

Adis International

Access to resources Recommend Favorite

The ASCOT Trial: Clarifying the Role of ACE Inhibition in the Reduction of Cardiovascular Events in Patients with Hypertension

By Meurin Philippe  

American Journal of Cardiovascular Drugs, Vol. 6, Iss. 5, 2006-01 ,pp. : 327-334

Adis International

Access to resources Recommend Favorite

The Current Role of ACE-inhibitors for Secondary Prevention in Cardiovascular Disease; from Pathogenesis to Clinical Practice

By Voors Adriaan A.   Veldhuisen Dirk J.   Gilst Wiek H.  

Cardiovascular Drugs and Therapy, Vol. 20, Iss. 1, 2006-02 ,pp. : 69-73

Springer Publishing Company

Access to resources Recommend Favorite